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Abstract
Aims Little is known about the impact of sodium glucose co-transporter 2 (SGLT2) inhibitors on cardiac biomarkers, such as
natriuretic peptides, in type 2 diabetes (T2D) patients with concomitant chronic heart failure (CHF). We compared the effect of
canagliflozin with glimepiride, based on changes in N-terminal pro-brain natriuretic peptide (NT-proBNP), in that patient
population.
Methods and results Patients with T2D and stable CHF, randomized to receive canagliflozin 100 mg or glimepiride (starting-
dose: 0.5mg), were examined using the primary endpoint of non-inferiority of canagliflozin vs. glimepiride, defined as a margin
of 1.1 in the upper limit of the two-sided 95% confidence interval (CI) for the group ratio of percentage change in NT-proBNP
at 24 weeks. Data analysis of 233 patients showed mean left ventricular ejection fraction (LVEF) at randomization was
57.6 ± 14.6%, with 71% of patients having a preserved LVEF (≥50%). Ratio of NT-proBNP percentage change was 0.48 (95%
CI, 0.13 to 1.59, P = 0.226) and therefore did not meet the prespecified non-inferiority margin. However, NT-proBNP levels
did show a non-significant trend lower in the canagliflozin group [adjusted group difference; 74.7 pg/mL (95% CI, 159.3 to
10.9), P = 0.087] and also in the subgroup with preserved LVEF [58.3 (95% CI, 127.6 to 11.0, P = 0.098]).
Conclusions This study did not meet the predefined primary endpoint of changes in NT-proBNP levels, with 24 weeks of
treatment with canagliflozin vs. glimepiride. Further research is warranted to determine whether patients with heart failure
with preserved ejection fraction, regardless of diabetes status, could potentially benefit from treatment with SGLT2 inhibitors.
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Introduction
Accumulating evidence suggests that type 2 diabetes (T2D) is
a major risk factor of cardiac dysfunction and heart failure
(HF), independent of hypertension and coronary artery dis-
ease, and concomitant HF strongly contributes to a worsened
prognosis.1 Recent large-scale randomized trials on cardiovas-
cular outcomes with newer glucose-lowering agents have
shown some agents have a large impact on the components
of cardiovascular diseases including HF.2 Among T2D
treatments, sodium glucose co-transporter 2 (SGLT2) inhibi-
tors markedly reduced hospitalization for HF in patients with
T2D at high risk for cardiovascular events, irrespective of car-
diovascular disease history including HF.3 In addition to the
blood glucose-lowering effect, SGLT2 inhibitors have
non-glycemic effects, such as reduction in blood pressure,
body weight, excess plasma fluid, and the risk of cardiovascu-
lar and renal events.4,5 However, those cardiovascular out-
comes trials included few participants with concomitant HF,
and their HF types were not phenotyped. More recently,
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dapagliflozin also significantly reduced the risk of worsening
HF or cardiovascular death even in both diabetic and
non-diabetic patients with HF and a reduced ejection
fraction.6 These results suggest that SGLT2 inhibitors have
favourable effects in patients with HF, irrespective of T2D,
and have advantages for HF care. Nevertheless, the profound
drivers of SGLT2 inhibitors for beneficial impact on HF are still
uncertain.7 Furthermore, the effects of SGLT2 inhibitors on
cardiac function or neurohumoral factors, such as natriuretic
peptides, are still not fully understood.
We therefore undertook a randomized trial comparing
canagliflozin with glimepiride, which has been associated with
decreases in HbA1c levels similar to canagliflozin 100 mg,8
with the primary objective of assessing the effect of
canagliflozin on N-terminal pro-brain natriuretic peptide
(NT-proBNP) levels in T2D patients with chronic HF (CHF).
Methods
Study design and participants
The CANDLE trial (UMIN000017669) was an investigator-
initiated, multicentre, prospective, randomized, open-label,
blinded-endpoint trial at 34 centres in Japan. The detailed ra-
tionale and design have been described previously.9 Briefly,
individuals aged 20 years or older with appropriately diag-
nosed T2D and New York Heart Association (NYHA) class I–
III CHF were eligible. CHF was defined by skilled cardiologists
according to the clinical signs or symptoms associated with
the Framingham criteria for congestive HF, relevant findings
based on physiological and laboratory tests, and a docu-
mented history of HF. Participants’ NYHA class and medical
treatment for CHF could not change up to 4 weeks prior to
eligibility screening. Regarding glycemic control, patients with
T2D who were under poor or suboptimal control were eligi-
ble. Key exclusion criteria were severe renal dysfunction (es-
timated glomerular filtration rate < 45 mL/min/1.73m2),
CHF with NYHA class IV, and history of cardiovascular disease
needing revascularization within 3 months of screening.
The trial was approved by individual sites’ institutional re-
view boards and independent ethics committees, in compli-
ance with the Declaration of Helsinki and the current legal
regulations in Japan. All enrolled patients provided written in-
formed consent prior to eligibility screening.
Randomization
All participants who met the enrolment criteria were ran-
domly assigned (1:1) to treatment with canagliflozin or
glimepiride. Treatment assignment was carried out with a
web-based program with the minimization method with bi-
assed coin assignment balancing for age (<65, ≥65 yr), HbA1c
level (<6.5%, ≥6.5%), and left ventricular ejection fraction
(LVEF; <40%, ≥40%) at the time of screening.
Procedures
After randomization, patients were started on canagliflozin
100mg once daily or glimepiride 0.5mg once daily. The inter-
vention design spanned 24 weeks. Although no specific nu-
merical goal for HbA1c level was set in this trial, all patients
were treated according to the Japanese treatment guidelines
for diabetes. For patients who could not achieve their glyce-
mic goal, increasing the dose of background therapy or
adding glucose-lowering agents other than SGLT2 inhibitors
and sulfonylureas in both groups was allowed. In the
glimepiride group, a dose increase of up to 6.0 mg daily
was permitted. Given that these modes in principle and if
possible, unchanged during the study period. However, the
dose of diuretics could be tapered if considered clinically ap-
propriate in order to avoid excess diuresis and subsequent
dehydration caused by co-administration of canagliflozin.
The intervention period was of 24 weeks duration.
Endpoints
The primary endpoint was the percentage change (post/pre
1) from baseline in NT-proBNP at Week 24. In the second-
ary endpoints, we evaluated the changes in parameters after
24 weeks of treatment or at early termination visits, including
(1) NT-proBNP level, (2) vital signs (body weight, blood pres-
sure, and heart rate), (3) glycemic control (HbA1c, fasting
plasma glucose), (4) estimated plasma volume (ePV) calcu-
lated by the Strauss formula (Method S1),10,11 (5) echocardio-
graphic measures (LVEF and mitral inflow to mitral relaxation
velocity ratio; E/e′), (6) NYHA functional classification, and (7)
CHF-related quality of life evaluated by scaled responses to
the Minnesota Living with Heart Failure (MLHF) question-
naire. As a safety endpoint, we also analysed the prevalence
of prespecified and adjudicated clinical events, including hos-
pitalization for HF, which were adjudicated according to the
predefined evaluation criteria (Method S2) by an indepen-
dent clinical event committee. We also assessed the inci-
dence of adverse events throughout the study period.
NT-proBNP was assessed at baseline and Week 24 or at
early termination visits and measured at a central laboratory
(SRL, Inc. Tokyo, Japan) with an electrochemiluminescence
immunoassay (Roche, Basel, Switzerland) under blindness
for allocation.
Echocardiography was performed at screening, baseline,
and Week 24 or at early termination visits to measure systolic
and diastolic function at each local site. We used the mean e′
in the septal and lateral side.
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Statistical analysis
In the power calculation, based on the previous study,12 we
assumed an 18% difference in the changes in NT-proBNP
from baseline to 24 weeks between the two groups and a
common standard deviation for the log scale of the ratio of
0.80. We estimated that it was necessary to recruit 125 pa-
tients in each group to demonstrate non-inferiority of
canagliflozin vs. glimepiride, ensuring at least 80% power to
detect 18% difference, using a one-sided t-test with an α level
of 0.025 and a non-inferiority margin of 1.1 in the upper limit
of the two-sided 95% confidence interval (CI) for the group
ratio of the percentage changes from baseline to 24 weeks
in NT-proBNP levels and a dropout rate of 10%.
We analysed the primary and secondary efficacy variables
by comparing all patients who received at least one dose of
treatment during the study period and had no serious proto-
col deviations (full analysis set), and changes in the variables
were compared based on data from patients who had baseline
and 24-week assessments. The incidence of adverse events
was analysed with data collected after randomization (safety
analysis set). To assess the primary endpoint, a group ratio of
percentage changes in NT-proBNP and their 95% CI were cal-
culated with Fieller’s method. The baseline-adjusted means
and 95% CIs estimated by analysis of covariance for the abso-
lute change in NT-proBNP level at 24 weeks were compared
between the two treatments. Post hoc responder analyses
were also conducted to investigate the proportions of patients
who had a clinically meaningful change (20% or greater) in
NT-proBNP level from baseline to 24 weeks,13 while a logistic
regression model adjusted for corresponding baseline
NT-proBNP values was used to assess the effect of
canagliflozin vs. glimepiride. Other comparisons of the
changes in parameters between the treatment groups were
performed using Student’s t-test or Wilcoxon rank-sum test
for changes in NYHA classification. No adjustment for multi-
plicity was considered for the secondary and post hoc efficacy
endpoints. Statistical testing was carried out at the two-sided
significance level of 0.05 and estimated effect sizes and their
95% CIs, and all statistical analyses were performed using
SAS software version 9.4 (SAS Institute, Cary, NC, USA).
Results
Study population
Between August 2015 and June 2017, 253 patients were
assessed for the study eligibility, of whom eight were ex-
cluded before randomization. A total of 245 patients were
randomized, of whom 228 patients completed 24 weeks of
treatment, and 241 and 233 were included in the safety anal-
ysis set and full analysis set, respectively (Figure 1). In the
glimepiride group, the median daily dose of glimepiride at
the final visit was 1.0 mg (interquartile range 0.5, 1.0).
Baseline characteristics were comparable between treat-
ment groups (Table 1). The patients were elderly
(68.6 ± 10.1 yrs), and most were male patients (75%) and well
controlled in blood pressure and NYHA functional class I
(64%) or II (34%). Overall, 24% had a history of myocardial in-
farction, and the aetiology of CHF in 43% was ischemia. Mean
LVEF at randomization was 57.6 ± 14.6%, with 71% of pa-
tients having a reduced LVEF (≥50%). Most patients had been
taking renin–angiotensin–aldosterone system blockers and
statins before enrolment. Approximately 40% had been pre-
scribed diuretics. The baseline level of HbA1c was 7.0 ± 0.8%.
N-terminal pro-brain natriuretic peptide
The details of NT-proBNP levels at baseline and 24 weeks are
shown in Table S1. The mean percentage changes were
10.4% (95% CI, 0.54 to 21.26) in the canagliflozin group
and 21.5% (95% CI, 7.18 to 35.77) in the glimepiride group,
with a group ratio of percentage changes (canagliflozin vs.
glimepiride) of 0.48 (95% CI, 0.13 to 1.59, P = 0.226, Figure
2A). The responder analyses (Figure 2B–D) showed that a
larger proportion of patients treated with canagliflozin, espe-
cially those with preserved LVEF (≥50%), had a ≥ 20% reduc-
tion in NT-proBNP levels. However, there was no significant
difference in this proportion between the two treatment
groups (Table S2). Similarly, a numerically smaller proportion
of patients treated with canagliflozin, especially subjects with
a reduced LVEF (<50%), had a ≥ 20% increase in NT-proBNP
levels, with no significant difference in this proportion be-
tween the two groups.
A greater reduction in NT-proBNP levels was observed in all
the patients treated with canagliflozin, although there was no
significant difference in baseline-adjusted mean changes in
NT-proBNP levels between canagliflozin and glimepiride
[78.7 pg/mL (95% CI, 139.9 to 17.5) vs. 4.5 pg/mL
(95% CI, 63.4 to 54.4), P = 0.087]. Data stratified according
to baseline NT-proBNP levels using the overall median value
of 252 pg/mL and guideline-recommended cut-off values for
diagnosing HF14,15 showed canagliflozin treatment reduced
NT-proBNP levels to a greater extent than in subgroups with
elevated levels of NT-proBNP, especially the subgroup with a
baseline NT-proBNP level ≥ 125 pg/mL [121.5 pg/mL (95%
CI, 201.7 to 41.2) vs. 6.1 pg/mL (95% CI, 86.9 to
74.7), P = 0.047; Figure 3A and Table 2]. Subgroup analyses
based on the baseline LVEF showed the group difference in ad-
justed mean change in NT-proBNP level was 10.0 pg/mL in pa-
tients with reduced LVEF (95% CI, 204.2 to 224.3, P = 0.926)
and 58.3 pg/mL (95% CI, 127.6 to 11.0, P = 0.098) in pa-
tients with preserved LVEF (Figure 3B,C). The reduction in
NT-proBNP levels driven by canagliflozin in subgroups with el-
evated levels of the hormone was more apparent in patients
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with preserved LVEF than in those with a reduced LVEF
(Table S3).
Clinical parameters of interest
The changes in clinical and laboratory parameters of interest
are summarized in Table S4. A larger reduction in HbA1c level
was observed in the glimepiride group. Differences in
changes in blood pressures and heart rate were not signifi-
cant between treatment groups. The body weight reduction
in the canagliflozin group was significantly larger than that
in the glimepiride group. Canagliflozin treatment increased
haemoglobin and haematocrit levels to a greater extent than
glimepiride. In addition, 24 weeks of canagliflozin treatment
significantly reduced ePV to a greater extent than that ob-
served with glimepiride, irrespective of the baseline LVEF
levels (Figure 4A).
Cardiac function, New York Heart Association
class, and Minnesota Living with Heart Failure
score
We measured no significant changes in echocardiographic pa-
rameters related to the left ventricular systolic and diastolic
function (Table S5). Overall, changes in the NYHA class were
comparable between groups (P = 0.061), whereas in the sub-
group with a baseline LVEF ≥50% canagliflozin caused a signif-
icant improvement in NYHA classes compared with that
found for glimepiride treatment (P = 0.027; Figure 4B). Al-
though the total MLHF scores at baseline were not balanced
and were lower in the canagliflozin group than in the
glimepiride group (11.5 ± 12.7 vs. 16.5 ± 16.8, P = 0.012).
However, there was no significant difference in
baseline-adjusted mean changes in the total score at
24 weeks between canagliflozin and glimepiride (Table S6).
Adjudicated clinical and adverse events
Any adverse events were reported in nine patients (10 events)
in the canagliflozin group and 13 patients (17 events) in the
glimepiride group (Table S7). In the canagliflozin group, two
patients (1.7%) had the prespecified and adjudicated clinical
events, one non-fatal stroke and one investigator-reported
worsening of HF; in the glimepiride group, five patients
(4.1%) experienced those events, three investigator-reported
worsening of HF events, leading to hospitalization in one pa-
tient, and two all-cause deaths. In the canagliflozin group, nei-
ther hypoglycemia nor urinary tract/genital infection was
reported, but two adverse events possibly associated with
Figure 1 Flow chart of the study.
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the study drug were observed: one osmotic diuresis-related
symptom and one hypovolemia-related symptom.
Discussion
In this trial we observed that (1) canagliflozin treatment given
for 24 weeks to Japanese elderly patients with T2D and stable
CHF did not meet the predefined primary endpoint (non-infe-
riority for the group ratio of percentage change in NT-proBNP
level) possibly because of the large variation in these levels; (2)
the reduction in NT-proBNP, a key secondary endpoint, was
numerically greater in the canagliflozin group than in the
glimepiride group, especially in patients with elevated
NT-proBNP levels; (3) in the subgroup with HFpEF canagliflozin
reduced NT-proBNP level and improved NYHA functional class
to a greater extent than glimepiride; (4) canagliflozin signifi-
cantly reduced ePV irrespective of baseline LVEF levels, al-
though there was no significant effect on MLHF score.
At the time of designing the current trial, no one knew if
SGLT2 inhibitors could reduce NT-proBNP and even improve
HF-related outcomes. There was also no direct evidence
showing that sulfonylureas can increase or decrease the risk
of HF. Therefore, we speculated that canagliflozin might be
non-inferior to glimepiride in regard to the effect on
NT-proBNP and performed this trial.
Recent cardiovascular outcome trials with SGLT2 inhibitors
in patients with T2D at high risk of cardiovascular events have
demonstrated beneficial effects of SGLT2 inhibitors on
HF-related outcomes, which have become a centre of
attention.16 Intriguingly, those trials showed a consistent risk
reduction in HF-related outcomes, and such beneficial effects
Table 1 Baseline demographic and characteristics
Variable Canagliflozin (n = 113) Glimepiride (n = 120)
Age, year 68.3 ± 9.8 68.9 ± 10.4
Female 25 (22.1) 34 (28.3)
Body mass index, kg/m2 24.1 ± 6.4 25.4 ± 4.8
Systolic blood pressure, mm Hg 124.9 ± 14.3 124.5 ± 18.0
History
Hypertension 49 (43.4) 53 (44.2)
Dyslipidemia 46 (40.7) 54 (45.0)
Myocardial infarction 32 (28.3) 24 (20.0)
Angina pectoris 24 (21.2) 27 (22.5)
Coronary artery bypass grafting 12 (10.6) 10 (8.3)
Stroke 11 (9.7) 5 (4.2)
Heart failure cause*
Ischemia 54 (47.8) 46 (38.3)
Hypertension 32 (28.3) 30 (25.0)
Valve 19 (16.8) 17 (14.2)
Dilated cardiomyopathy 17 (15.0) 19 (15.8)
Arrhythmia 29 (25.7) 33 (27.5)
Heart failure status
NYHA functional class
I 72 (63.7) 76 (63.9)
II 39 (34.5) 40 (33.6)
III 2 (1.8) 3 (2.5)
Unknown 0 (0.0) 1
LVEF <50% 35 (31.0) 33 (27.5)
Medication
Non-diabetic
ACE inhibitor or ARB 89 (78.8) 88 (73.3)
Beta-blocker 82 (72.6) 82 (68.3)
Calcium channel blocker 46 (40.7) 44 (36.7)
MRA 42 (37.2) 44 (36.7)
Diuretic 46 (40.7) 53 (44.2)
Digitalis 12 (10.6) 8 (6.7)
Statin 87 (77.0) 86 (71.7)
Anti-platelet or anti-coagulant 71 (62.8) 66 (55.0)
Diabetic
Insulin 4 (3.5) 3 (2.5)
Metformin 18 (15.9) 26 (21.7)
Alpha-glucosidase inhibitor 16 (14.2) 24 (20.0)
DPP-4 inhibitor 64 (56.6) 63 (52.5)
GLP-1RA 1 (0.9) 1 (0.8)
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; DPP-4, dipeptidyl peptidase-4; GLP-1RA, glucagon-like peptide-1
receptor agonist; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association.
Data are mean ± standard deviation or n (%).
*Multiple answers were allowed.
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Figure 2 Percentage changes in NT-proBNP levels between baseline and 24 weeks and responder analyses. (A) Percentage changes in NT-proBNP
levels from baseline to 24 weeks and the group ratio (canagliflozin vs. glimepiride). (B–D) Proportion of all patients showing a clinically meaningful
change in NT-proBNP levels at 24 weeks. (B) Overall. (C) HFrEF (defined as baseline LVEF <50%). (D) HFpEF (defined as baseline LVEF ≥50%). HFpEF,
heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LVEF, left ventricular ejection fraction; NT-proBNP,
N-terminal pro-brain natriuretic peptide.
Figure 3 Adjusted mean change in NT-proBNP levels. (A) Adjusted mean change in NT-proBNP levels in all the patients and subgroups stratified ac-
cording to baseline NT-proBNP levels. Detailed values and statistics are shown in Table 2. (B–C) Adjusted mean change in NT-proBNP levels and group
differences (canagliflozin–glimepiride) in HFrEF (B) and HFpEF (C).
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were consistent across a broad spectrum of clinical character-
istics, irrespective of baseline HF.3 In our study, canagliflozin
treatment, compared with glimepiride, reduced NT-proBNP
in patients with elevated levels of NT-proBNP. In a recent
substudy from the DECLARE-TIMI 58 trial,17 dapagliflozin
treatment also showed a significantly greater absolute risk re-
duction in cardiovascular death or hospitalization for HF in
patients with higher baseline NT-proBNP levels [>75 pg/mL
(median)]. This suggested SGLT2 inhibitors have greater clin-
ical benefit in patients with elevated NT-proBNP levels irre-
spective of overt HF.
Few randomized clinical trials have to date investigated the
effect of SGLT2 inhibitors on NT-proBNP as a measure of
treatment impact on HF. Januzzi et al. first reported that
canagliflozin slowed the rise in NT-proBNP, relative to pla-
cebo, over 2 years in older patients with T2D.18 Because
the baseline levels of NT-proBNP in those patients were
markedly lower than patients in our trial, only a few patients
with overt CHF were likely to have been enrolled in that
study. More recently, the use of dapagliflozin over 12 weeks
did not affect NT-proBNP levels in patients with HFrEF, al-
though it increased the proportion of patients who experi-
enced clinically meaningful improvements in HF-related
health status or natriuretic peptides levels.13 Nevertheless,
the DAPA-HF trial in a similar population demonstrated that
the risk of worsening HF or cardiovascular death was lower
in the dapagliflozin group than placebo.6 Therefore, despite
having limited effects on NT-proBNP levels, SGLT2 inhibitors
improved clinical outcomes in patients with HFrEF. These
conflicting findings should be interpreted as indicating a pos-
sible disconnect between short-term changes in NT-proBNP
levels and clinical outcomes.
A recent subanalysis from the CANVAS program showed a
greater canagliflozin-mediated risk reduction in HFrEF events
compared with that observed in HFpEF events.19 Further-
more, in the DECLARE-TIMI 58 trial, dapagliflozin appeared
to be more effective for reducing the risk of cardiovascular
death and all-cause death in patients with HFrEF (LVEF
<45%) at baseline compared with those without HFrEF.20
These data suggest that the impact of SGLT2 inhibitors on
cardiovascular outcomes differs according to HF phenotype,
with patients with HFrEF being more affected by SGLT2 inhib-
itors than those with HFpEF. In our study, the adjusted mean
reduction in NT-proBNP associated with canagliflozin treat-
ment was also relatively smaller in patients with HFpEF com-
pared with those with HFrEF. Interestingly, canagliflozin
treatment reduced NT-proBNP levels more than glimepiride
in patients with HFpEF, and more patients with HFpEF had
improvement in NYHA status in the canagliflozin group com-
pared with glimepiride. These findings suggest that patients
with HFpEF can also benefit from SGLT2 inhibitors. However,
whether or not SGLT2 inhibitors improve HF-related out-
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trials. These trials will provide profound insights into the ef-
fects of SGLT2 inhibitors according to HF phenotypes.
The beneficial effects of SGLT2 inhibitors on risk reduction
in HF-related outcomes are primarily thought to result from
hemodynamic effects derived from glycosuria and
natriuresis.4 Specifically, SGLT2 inhibitor-induced reductions
in body weight are likely to be associated with a subsequent
reduction in other components, such as interstitial fluid and
fat mass.21 Regarding the effects on cardiac structure and
function, Verma et al. found that short-term of empagliflozin
treatment was associated with significant reduction in left
ventricular mass indexed to body surface area and improve-
ment of diastolic function in patients with T2D and established
cardiovascular disease.22,23 Interestingly, as shown in the
sub-analysis from the EMPA-REG OUTCOME trial,24 increased
haematocrit might help to supply oxygen to peripheral tissues
and mitigate HF-related symptoms. In our trial, canagliflozin
treatment was also associated with hemoconcentration and
a resultant decrease in ePV, suggesting potential clinical bene-
fits in T2D patients with concomitant CHF. However, the de-
tailed mechanisms by which SGLT2 inhibitors exert their
beneficial effects on HF remain to be determined,7 because
of the recent striking findings from the DAPA-HF trial that
showed a marked reduction in risk for HF-related outcomes
even in patients with established HFrEF regardless of T2D.6
Further studies to elucidate drug-specific pathophysiological
protection against myocardial injury and cardiomyocyte death
are therefore warranted.25
Limitations
First, the trial was an open-label design and not placebo con-
trolled and accordingly there might have been bias towards
the assessment of outcomes resulting from the investigators’
choice of background treatment and subjective manner.
Second, the analysis was not based on the intention-to-treat
manner, and the sample size was small, and the relatively
short follow-up period of 24 weeks may have limited the ef-
fects of the outcomes measured. Third, the CHF status at
baseline was evaluated by local investigators based solely
on the clinical manifestations and documented history of
HF. Because we did not use cut-off levels of NT-proBNP to
avoid unforeseen misdiagnosis of CHF, it was therefore diffi-
cult to exclude patients with low levels of NT-proBNP and fur-
ther confirm baseline CHF status. Furthermore, no robust
effects on HF-related parameters may have resulted as a con-
sequence of the mild and stable CHF status at baseline.
Fourth, natriuretic peptides have substantial biological and
analytic variation, and outliers may have had a potential influ-
ence on the statistical analyses. Furthermore, the absolute
value of natriuretic peptide levels in outpatients reflects the
cardiac load because of the latest activity rather than the
state of CHF, and therefore, this value does not necessarily
reflect the severity of CHF. It might also have been insuffi-
cient to evaluate the therapeutic impact of the study drugs
on CHF at only one study visit, thereby limiting the use of bio-
markers as a surrogate endpoint in relevant clinical trials.26 Fi-
nally, because the trial included only Japanese patients, we
cannot generalize the findings to other ethnicities. Moreover,
the dose of canagliflozin used was limited to 100 mg daily.
Conclusions
The present study did not meet the predefined primary end-
point with respect to the percentage change in NT-proBNP
levels, with 24 weeks of canagliflozin treatment, relative to
glimepiride, showing no robust effects on NT-proBNP in pa-
tientswith T2Dand clinically stable CHF. Further research iswar-
ranted to determine whether patients with HF with preserved
Figure 4 Changes in ePV and NYHA Class. (A) Percentage changes in ePV between baseline and 24 weeks, calculated by the Strauss formula and the
group differences (canagliflozin vs. glimepiride) in all the patients and those with HFrEF or HFpEF. (B) Proportion of patients who worsened, remained
unchanged, or improved their NYHA class in all the patients and those with HFrEF or HFpEF.
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ejection fraction, regardless of diabetes status, could potentially
benefit from treatment with SGLT2 inhibitors.
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